Compliance & Ethics

Senior officials from the SEC, FDIC, CFTC, Federal Reserve Board, and Bank of England held a tabletop exercise on Sept. 3, 2026, to discuss the hypothetical resolution of central counterparties (CCPs). The meeting focused on information sharing and communication arrangements to support financial stability. It introduces no new requirements, but it signals continued cross-border supervisory attention to CCP resilience, which matters for firms with significant clearing exposures.

EIOPA rejected Question 3463 because it sought an interpretation of French national legislation, which is outside the scope of the Q&A process. No new guidance on CIC codes for NEU CP or NEU MTN was issued. Insurers must therefore rely on existing Solvency II reporting rules and their own documented classification judgment.

On September 11, 2026, the Austrian Financial Market Authority (FMA) issued a public warning that Clear Markets Europe, apparently based in London, is not authorized to conduct licensable securities transactions in Austria. The firm may not execute client orders under the Securities Supervision Act 2018 (WAG 2018). Compliance teams should treat the entity as a high-risk, unlicensed counterparty and update screening and fraud controls accordingly.

The Norway Financial Supervisory Authority (Finanstilsynet) has listed a warning about MPay Global, an entity flagged by the United Kingdom's Financial Conduct Authority (FCA). The source content is minimal, so the specific misconduct is not stated and must be confirmed in the FCA notice. Compliance teams should screen for any exposure to the entity and update their watchlists.

Japan's Financial Services Agency has published draft amendments to the Comprehensive Supervisory Guidelines for Insurance Companies and is soliciting public comments until October 13, 2026. The draft restructures regulations on in-house agents, establishes antitrust compliance system expectations, and enhances monitoring of non-life insurance products for corporations. Non-life insurers and related agencies should assess the impact now and decide whether to submit comments.

The French Financial Markets Authority (AMF) has opened applications for its 2026 "Young Researcher in Economics" prize, worth EUR $5,000, with a deadline of November 15, 2026. The prize carries no compliance obligations for regulated firms. It does signal the economic and financial research themes the AMF considers relevant to its regulatory work, which compliance teams may want to monitor.

Germany's Federal Data Protection Commissioner (BfDI) has issued recommendations urging the Federal Government to improve public information and give insured persons finely differentiated control over who can view their electronic patient record (ePA) data. From the end of October 2026, pseudonymized medication list data can be extracted from the ePA for research unless the insured person objects. Compliance teams at health-sector organizations and research partners should treat this as a signal of regulatory expectations for consent, transparency, and secondary use of health data.